The Future of Alzheimer's Pharmaceutical Aducanumab - as a Medicine and as a Financial Product - What Happens Now?
Yves here. This post from Health Care Renewal continues with its discussion of aducanumab, a drug so unlikely to make a material difference to Alzheimer’s victims that absent the mind-blowing price tag (estimated at $56,000 a year), it looks like Big Pharma’s answer to faith healing. It discusses what outcomes are probable, including the grotesque enrichment of its creator, Biogen, at the expense of patients and insurance programs, including Medicare. In other words, if you think aducanumab isn’t your problem, think twice. Medical-industrial complex grifting is the big reason the US has...
Source: nakedcapitalism.com